Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JASON C CHANDLER

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1295778330
CMS profile
104698
Location
GERMANTOWN, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$56,928.77

103 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JASON C CHANDLER

NPI 1295778330 · CMS profile ID 104698

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

GERMANTOWN, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295778330?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JASON C CHANDLER, NPI 1295778330, CMS profile ID 104698. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295778330?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JASON C CHANDLER, NPI 1295778330, CMS profile ID 104698. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295778330?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JASON C CHANDLER, NPI 1295778330, CMS profile ID 104698, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1295778330?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

103 matching records · $56,928.77 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 103 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–103 of 103.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SOBI, INC $21.3401/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240242688 CMS
Daiichi Sankyo Inc. $16.5001/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197075957 CMS
Genentech USA, Inc. $16.7401/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211521447 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,466.27 83
PY2020 $10,120.82 41
PY2021 $39,670.28 35
PY2022 $18,855.65 25
PY2023 $56,803.30 64
PY2024 $44,813.81 63
PY2025 $56,928.77 103

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $634,772.37 49
PY2024 Recipient $989.11 4
PY2024 Principal investigator $237,912.77 30
PY2023 Principal investigator $264,761.17 24
PY2022 Principal investigator $52,703.93 14
PY2021 Principal investigator $19,888.86 6
PY2020 Principal investigator $71,993.00 15
PY2019 Principal investigator $62,122.32 25

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

49 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $144.00 12/31/2025 Non-covered Recipient Entity
WEST CLINIC PC
A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting No dispute reported 06/30/2026 1202533765
Principal investigator 1 ABBVIE INC. $2,640.60 12/23/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202531834
Principal investigator 1 ABBVIE INC. $6,847.20 12/04/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202529028
Principal investigator 1 ABBVIE INC. $300.00 11/26/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202525498
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,381.00 11/26/2025 Non-covered Recipient Entity
The West Clinic, Pllc Dba West Cancer Center
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) No dispute reported 06/30/2026 1235992949
Principal investigator 1 Incyte Corporation $5,660.53 11/25/2025 Non-covered Recipient Entity
WEST CANCER CENTER AND RESEARCH INSTITUTE
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240618438
Principal investigator 1 Incyte Corporation $6,976.16 11/10/2025 Non-covered Recipient Entity
WEST CANCER CENTER AND RESEARCH INSTITUTE
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240618442
Principal investigator 1 ABBVIE INC. $7,059.15 11/05/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202521977
Principal investigator 1 Genentech, Inc. $8,231.00 11/05/2025 Non-covered Recipient Entity
The West Clinic PLLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211671780
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $64,033.00 11/03/2025 Non-covered Recipient Entity
The West Clinic, Pllc Dba West Cancer Center
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1235992951
Principal investigator 1 Genentech, Inc. $5,569.00 10/20/2025 Non-covered Recipient Entity
The West Clinic PLLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211671778
Principal investigator 1 ABBVIE INC. $8,819.55 10/09/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202515425
Principal investigator 1 ABBVIE INC. $16,538.94 09/18/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202511336
Principal investigator 1 ABBVIE INC. $2,090.00 09/18/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202511350
Principal investigator 1 ABBVIE INC. $1,023.00 09/17/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202511138
Principal investigator 1 ABBVIE INC. $24,389.10 09/04/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202508606
Principal investigator 1 ABBVIE INC. $1,557.00 08/21/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202505455
Principal investigator 1 Genentech, Inc. $6,678.00 08/08/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211684892
Principal investigator 1 ABBVIE INC. $3,792.15 08/06/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202503051
Principal investigator 1 Genentech, Inc. $6,583.00 07/29/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211684888
Principal investigator 1 ABBVIE INC. $1,000.00 07/24/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202499548
Principal investigator 1 ABBVIE INC. $375.30 07/15/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202498234
Principal investigator 1 Genentech, Inc. $2,757.00 07/07/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211684890
Principal investigator 1 ABBVIE INC. $19,423.80 07/02/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202494983
Principal investigator 1 ABBVIE INC. $596.00 06/13/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202491407
Principal investigator 1 Genentech, Inc. $6,433.00 05/28/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211684878
Principal investigator 1 Genentech, Inc. $18,294.00 05/14/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211684882
Principal investigator 1 ABBVIE INC. $2,371.82 05/06/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202482049
Principal investigator 1 ABBVIE INC. $792.00 05/01/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202480831
Principal investigator 1 Genentech, Inc. $6,855.00 04/29/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211684880
Principal investigator 1 Celgene Corporation $35,283.00 04/28/2025 Non-covered Recipient Entity
Margaret West Comprehensive Breast Center
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) No dispute reported 06/30/2026 1222305312
Principal investigator 1 Eli Lilly and Company $23,755.00 04/28/2025 Non-covered Recipient Entity
THE WEST CLINIC
A PHASE 2, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF 3 DOSES OF PIRTOBRUTINIB IN PARTICIPANTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WHO PREVIOUSLY RECEIVED TREATMENT WITH A COVALENT BRUTON TYROSINE KINASE INHIBITOR No dispute reported 06/30/2026 1187892538
Principal investigator 1 ABBVIE INC. $2,764.00 04/15/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202476564
Principal investigator 1 Incyte Corporation $5,762.90 04/15/2025 Non-covered Recipient Entity
WEST CANCER CENTER AND RESEARCH INSTITUTE
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240618434
Principal investigator 1 ABBVIE INC. $12,036.00 04/03/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202473172
Principal investigator 1 ABBVIE INC. $2,371.82 04/03/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202473175
Principal investigator 1 ABBVIE INC. $792.00 04/03/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202473180
Principal investigator 1 Genentech, Inc. $13,000.00 04/01/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211684884
Principal investigator 1 Genentech, Inc. $3,544.00 04/01/2025 Non-covered Recipient Entity
WEST CLINIC PC RESEARCH ACCOUNTING
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211684886
Principal investigator 1 ABBVIE INC. $2,371.82 03/06/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202457902
Principal investigator 1 ABBVIE INC. $1,175.00 02/27/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202454323
Principal investigator 1 Incyte Corporation $1,000.00 02/25/2025 Non-covered Recipient Entity
WEST CANCER CENTER AND RESEARCH INSTITUTE
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240618430
Principal investigator 1 Eli Lilly and Company $1,627.05 02/10/2025 Non-covered Recipient Entity
THE WEST CLINIC
A PHASE 2, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF 3 DOSES OF PIRTOBRUTINIB IN PARTICIPANTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WHO PREVIOUSLY RECEIVED TREATMENT WITH A COVALENT BRUTON TYROSINE KINASE INHIBITOR No dispute reported 06/30/2026 1187893186
Principal investigator 1 ABBVIE INC. $2,371.82 02/05/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202444366
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,463.91 01/27/2025 Non-covered Recipient Entity
West Cancer Center
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) No dispute reported 06/30/2026 1235991710
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,954.93 01/27/2025 Non-covered Recipient Entity
The West Clinic, Pllc Dba West Cancer Center
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1235992947
Principal investigator 1 ABBVIE INC. $588.00 01/14/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202438298
Principal investigator 1 Celgene Corporation $267,329.00 01/10/2025 Non-covered Recipient Entity
Margaret West Comprehensive Breast Center
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1222305272
Principal investigator 1 ABBVIE INC. $2,371.82 01/02/2025 Non-covered Recipient Entity
THE WEST CLINIC PLLC
M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202434039